Bejelentkezés Regisztrálj ingyen

Suda Pharmaceuticals Ltd Bevétel Q/Q

Mi az Suda Pharmaceuticals Ltd Bevétel Q/Q?

A Bevétel Q/Q az Suda Pharmaceuticals Ltd - -69.23%

Mi a Bevétel Q/Q meghatározása?

A negyedéves árbevétel-növekedés évről évre meghaladja a társaság bevételeinek növekedését az előző év azonos negyedévének százalékos arányában kifejezett teljesítményéhez képest.

Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.

Bevétel Q/Q a Health Care szektor a ASX-on cégekben a Suda Pharmaceuticals Ltd -hoz képest

Mit csinál Suda Pharmaceuticals Ltd?

Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.

bevétel q/q -hoz hasonló cégek Suda Pharmaceuticals Ltd